0001209191-18-026832.txt : 20180430 0001209191-18-026832.hdr.sgml : 20180430 20180430160334 ACCESSION NUMBER: 0001209191-18-026832 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180426 FILED AS OF DATE: 20180430 DATE AS OF CHANGE: 20180430 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHERWIN STEPHEN A CENTRAL INDEX KEY: 0001079462 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 18789605 MAIL ADDRESS: STREET 1: C/O CELL GENESYS, INC. STREET 2: 500 FORBES BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-04-26 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001079462 SHERWIN STEPHEN A 12780 EL CAMINO REAL SAN DIEGO CA 92130 1 0 0 0 Common Stock 2018-04-26 4 M 0 15000 7.05 A 58879 D Common Stock 2018-04-26 4 F 0 1331 79.44 D 57548 D Non-Qualified Stock Option 7.05 2018-04-26 4 M 0 15000 7.05 D 2011-06-25 2018-05-25 Common Stock 15000 0 D The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2011, which, if unexercised would have expired on May 25, 2018. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's 2003 Incentive Stock Plan, as amended. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($7.05) was subtracted from the April 26, 2018 market close price ($79.44), and this net amount ($72.39) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,669 shares to the optionee. The 1,331 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. /s/ Darin Lippoldt, Attorney-in-Fact 2018-04-30